★ Tissue Repair

Wolverine Blend

Tissue Repair · 10mg × 10 vials

BPC-157 + TB-500 in one vial. The classic soft-tissue repair pairing in research.

✓ 98%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support

📋 Certificate of Analysis Request the third-party COA via Telegram ↗

Overview

What Is Wolverine Blend?

Wolverine Blend is a single-vial co-formulation of BPC-157 and TB-500 in a 1:1 ratio by mass. The two peptides act through separate, non-overlapping repair mechanisms, which is the basis for studying them together, and co-formulation does not alter the pharmacology of either. BPC-157 (a 15-amino-acid pentadecapeptide derived from a protective sequence in human gastric juice) acts mostly locally: it upregulates VEGFR2 and drives capillary formation into damaged tissue, modulates the nitric oxide system to protect against ischaemia-reperfusion injury, and upregulates growth hormone receptor expression on fibroblasts, the proposed link to the GH axis in tendon repair.

TB-500 (the N-acetyl active fragment of thymosin beta-4) acts systemically: it binds G-actin monomers and regulates actin cytoskeleton assembly, the process that allows cells to migrate to injury sites, build new tissue, and form new vessels. Downstream, it upregulates VEGF and other angiogenic factors, activates progenitor and endothelial cells into the wound bed, and dampens TNF-alpha and NF-kB signalling. Together the two components cover angiogenesis, cell migration, tissue remodelling, and inflammation resolution, the full repair cycle described in the connective-tissue literature. No head-to-head trial of the combination exists.

Published Safety Data

What the published studies measured.

What the studies show

Measured in clinical trials

Combined-blend human RCT data does not exist. The blend has not been studied as a single product in any published trial. Safety profile is inferred from the individual components, both of which have been studied at the doses delivered by the blend.
BPC-157 component: no documented serious adverse events in published human studies (small Phase 1/2 Sikiric work + IBD pilots). Animal toxicology shows no signal at doses orders of magnitude above the human research dose. Total published human exposure is low hundreds of subjects.
TB-500 component: RegeneRx Phase 2 acute MI trial (~42 mg cumulative IV dose over 14 days) reported no drug-related serious adverse events. Phase 2 ophthalmic (dry eye) and pressure ulcer trials similarly reported mild local irritation only. No hepatic, renal, cardiovascular, or hormonal axis signal at studied doses.
Injection site reactions (redness, mild swelling): reported across trials of both components, typical of any SubQ peptide, mild and self-resolving.

The Research

Peer-reviewed studies and clinical guidelines - tap any to read the source.

PubMedSikiric et al, Curr Pharm Des 2018 - "Stable Gastric Pentadecapeptide BPC 157 as a Therapy" comprehensive review

foundational BPC mechanism + animal evidence

Read study ↗PubMedChang et al, J Appl Physiol 2011 - BPC 157 promotes tendon healing through VEGFR2

defines the VEGFR2 angiogenic mechanism for the BPC component

Read study ↗PubMedHsieh et al, J Orthop Res 2017 - "BPC 157 promotes tendon healing"

Achilles tendon transection model, tenocyte proliferation

Read study ↗PubMedGoldstein AL, Hannappel E, Kleinman HK - Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues, Trends Mol Med 2005

foundational TB-4 mechanism review by the field's lead researchers

Read study ↗PubMedCrockford D et al - Thymosin beta-4: structure, function, and biological properties, Ann NY Acad Sci 2010

TB-4 comprehensive properties review including wound healing, cardiac repair, neuroprotection